Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1988 Mar 1;167(3):903–913. doi: 10.1084/jem.167.3.903

Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component

PMCID: PMC2188867  PMID: 3351437

Abstract

Highly specific, high-resolution scintigraphic images of amyloid-laden organs in mice with experimentally induced amyloid A protein (AA) amyloidosis were obtained after intravenous injection of 123I-labeled serum amyloid P component (SAP). Interestingly, a much higher proportion (up to 40%) of the injected dose of heterologous human SAP localized to amyloid and was retained there than was the case with isologous mouse SAP, indicating that human SAP binds more avidly to mouse AA fibrils than does mouse SAP. Specificity of SAP localization was established by the failure of the related proteins, human C- reactive protein and Limulus C-reactive protein, to deposit significantly in amyloid and by the absence of human SAP deposition in nonamyloidotic organs. However, only partial correlations were observed between the quantity of SAP localized and two independent estimates, histology and RIA for AA of the amount of amyloid in particular organs. It is not clear which of the three methods used reflects better the extent or clinical significance of the amyloid deposits but in vivo localization of radiolabeled SAP, detectable and quantifiable by gamma camera imaging, is apparently extremely sensitive. These findings establish the use of labeled SAP as a noninvasive in vivo diagnostic probe in experimental amyloidosis, potentially capable of revealing the natural history of the condition, and suggest that it may also be applicable generally as a specific targeting agent for diagnostic and even therapeutic purposes in clinical amyloidosis.

Full Text

The Full Text of this article is available as a PDF (757.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axelrad M. A., Kisilevsky R., Willmer J., Chen S. J., Skinner M. Further characterization of amyloid-enhancing factor. Lab Invest. 1982 Aug;47(2):139–146. [PubMed] [Google Scholar]
  2. Baltz M. L., Caspi D., Evans D. J., Rowe I. F., Hind C. R., Pepys M. B. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol. 1986 Dec;66(3):691–700. [PMC free article] [PubMed] [Google Scholar]
  3. Baltz M. L., Dyck R. F., Pepys M. B. Studies of the in vivo synthesis and catabolism of serum amyloid P component (SAP) in the mouse. Clin Exp Immunol. 1985 Jan;59(1):235–242. [PMC free article] [PubMed] [Google Scholar]
  4. Benditt E. P., Eriksen N., Hanson R. H. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1979 Aug;76(8):4092–4096. doi: 10.1073/pnas.76.8.4092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Caspi D., Zalzman S., Baratz M., Teitelbaum Z., Yaron M., Pras M., Baltz M. L., Pepys M. B. Imaging of experimental amyloidosis with 131I-labeled serum amyloid P component. Arthritis Rheum. 1987 Nov;30(11):1303–1306. doi: 10.1002/art.1780301115. [DOI] [PubMed] [Google Scholar]
  6. Cathcart E. S., Skinner M., Cohen A. S. Immunogenicity of amyloid. Immunology. 1971 Jun;20(6):945–954. [PMC free article] [PubMed] [Google Scholar]
  7. Cohen A. S., Connors L. H. The pathogenesis and biochemistry of amyloidosis. J Pathol. 1987 Jan;151(1):1–10. doi: 10.1002/path.1711510102. [DOI] [PubMed] [Google Scholar]
  8. De Beer F. C., Pepys M. B. Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods. 1982;50(1):17–31. doi: 10.1016/0022-1759(82)90300-3. [DOI] [PubMed] [Google Scholar]
  9. Epenetos A. A., Britton K. E., Mather S., Shepherd J., Granowska M., Taylor-Papadimitriou J., Nimmon C. C., Durbin H., Hawkins L. R., Malpas J. S. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet. 1982 Nov 6;2(8306):999–1005. doi: 10.1016/s0140-6736(82)90046-0. [DOI] [PubMed] [Google Scholar]
  10. Epenetos A. A., Snook D., Hooker G., Lavender J. P., Halnan K. E. Tumour imaging using an improved method of DTPA-coupled monoclonal antibodies radiolabelled with metallic radionuclides. Lancet. 1984 Jul 21;2(8395):169–169. doi: 10.1016/s0140-6736(84)91087-0. [DOI] [PubMed] [Google Scholar]
  11. Esiri M. M., Wilcock G. K. Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry. 1986 Nov;49(11):1221–1226. doi: 10.1136/jnnp.49.11.1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gertz M. A., Brown M. L., Hauser M. F., Kyle R. A. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med. 1987 Jun;147(6):1039–1044. [PubMed] [Google Scholar]
  13. Glenner G. G. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980 Jun 5;302(23):1283–1292. doi: 10.1056/NEJM198006053022305. [DOI] [PubMed] [Google Scholar]
  14. Glenner G. G. Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N Engl J Med. 1980 Jun 12;302(24):1333–1343. doi: 10.1056/NEJM198006123022403. [DOI] [PubMed] [Google Scholar]
  15. Glenner G. G., Henry J. H., Fujihara S. Congophilic angiopathy in the pathogenesis of Alzheimer's degeneration. Ann Pathol. 1981;1(2):120–129. [PubMed] [Google Scholar]
  16. JANIGAN D. T. EXPERIMENTAL AMYLOIDOSIS: STUDIES WITH A MODIFIED CASEIN METHOD, CASEIN HYDROLYSATE AND GELATIN. Am J Pathol. 1965 Jul;47:159–171. [PMC free article] [PubMed] [Google Scholar]
  17. Kitamoto T., Tateishi J., Hikita K., Nagara H., Takeshita I. A new method to classify amyloid fibril proteins. Acta Neuropathol. 1985;67(3-4):272–278. doi: 10.1007/BF00687812. [DOI] [PubMed] [Google Scholar]
  18. Kula R. W., Engel W. K., Line B. R. Scanning for soft-tissue amyloid. Lancet. 1977 Jan 8;1(8002):92–93. doi: 10.1016/s0140-6736(77)91102-3. [DOI] [PubMed] [Google Scholar]
  19. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  20. Mandybur T. I. The incidence of cerebral amyloid angiopathy in Alzheimer's disease. Neurology. 1975 Feb;25(2):120–126. doi: 10.1212/wnl.25.2.120. [DOI] [PubMed] [Google Scholar]
  21. Maudsley S., Rowe I. F., de Beer F. C., Munn E. A., Herbert J., Feinstein A., Pepys M. B. Identification and isolation of two pentraxins from bovine serum. Clin Exp Immunol. 1987 Mar;67(3):662–673. [PMC free article] [PubMed] [Google Scholar]
  22. Osmand A. P., Friedenson B., Gewurz H., Painter R. H., Hofmann T., Shelton E. Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A. 1977 Feb;74(2):739–743. doi: 10.1073/pnas.74.2.739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pepys M. B., Baltz M. L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141–212. doi: 10.1016/s0065-2776(08)60379-x. [DOI] [PubMed] [Google Scholar]
  24. Pepys M. B., Baltz M. L., de Beer F. C., Dyck R. F., Holford S., Breathnach S. M., Black M. M., Tribe C. R., Evans D. J., Feinstein A. Biology of serum amyloid P component. Ann N Y Acad Sci. 1982;389:286–298. doi: 10.1111/j.1749-6632.1982.tb22144.x. [DOI] [PubMed] [Google Scholar]
  25. Pepys M. B., Dash A. C., Ashley M. J. Isolation of C-reactive protein by affinity chromatography. Clin Exp Immunol. 1977 Oct;30(1):32–37. [PMC free article] [PubMed] [Google Scholar]
  26. Pepys M. B., Dash A. C. Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet. 1977 May 14;1(8020):1029–1031. doi: 10.1016/s0140-6736(77)91260-0. [DOI] [PubMed] [Google Scholar]
  27. Pepys M. B., Dyck R. F., de Beer F. C., Skinner M., Cohen A. S. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979 Nov;38(2):284–293. [PMC free article] [PubMed] [Google Scholar]
  28. Pepys M. B. Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology. 1979 Jul;37(3):637–641. [PMC free article] [PubMed] [Google Scholar]
  29. Pontet M., Engler R., Jayle M. F. One step preparation of both human C-reactive protein and CIt. FEBS Lett. 1978 Apr 15;88(2):172–175. doi: 10.1016/0014-5793(78)80167-7. [DOI] [PubMed] [Google Scholar]
  30. Pras M., Zucker-Franklin D., Rimon A., Franklin E. C. Physical, chemical, and ultrastructural studies of water-soluble human amyloid fibrils. Comparative analyses of nine amyloid preparations. J Exp Med. 1969 Oct 1;130(4):777–796. doi: 10.1084/jem.130.4.777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Robey F. A., Liu T. Y. Limulin: a C-reactive protein from Limulus polyphemus. J Biol Chem. 1981 Jan 25;256(2):969–975. [PubMed] [Google Scholar]
  32. Rowe I. F., Jensson O., Lewis P. D., Candy J., Tennent G. A., Pepys M. B. Immunohistochemical demonstration of amyloid P component in cerebro-vascular amyloidosis. Neuropathol Appl Neurobiol. 1984 Jan-Feb;10(1):53–61. doi: 10.1111/j.1365-2990.1984.tb00340.x. [DOI] [PubMed] [Google Scholar]
  33. Westermark P., Shirahama T., Skinner M., Brun A., Cameron R., Cohen A. S. Immunohistochemical evidence for the lack of amyloid P component in some intracerebral amyloids. Lab Invest. 1982 May;46(5):457–460. [PubMed] [Google Scholar]
  34. Yood R. A., Skinner M., Cohen A. S., Lee V. W. Soft tissue uptake of bone seeking radionuclide in amyloidosis. J Rheumatol. 1981 Sep-Oct;8(5):760–766. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES